16,990 Shares in Exelixis, Inc. $EXEL Bought by Impact Partnership Wealth LLC

Impact Partnership Wealth LLC bought a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the first quarter, HoldingsChannel.com reports. The firm bought 16,990 shares of the biotechnology company’s stock, valued at approximately $729,000.

A number of other hedge funds also recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its holdings in Exelixis by 11.2% during the third quarter. Dimensional Fund Advisors LP now owns 4,180,912 shares of the biotechnology company’s stock valued at $172,658,000 after purchasing an additional 419,596 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Exelixis by 62.5% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 187,154 shares of the biotechnology company’s stock worth $8,224,000 after buying an additional 71,987 shares in the last quarter. Elo Mutual Pension Insurance Co raised its holdings in shares of Exelixis by 124.3% in the 3rd quarter. Elo Mutual Pension Insurance Co now owns 54,643 shares of the biotechnology company’s stock worth $2,257,000 after buying an additional 30,279 shares in the last quarter. Private Client Services LLC bought a new position in shares of Exelixis during the 4th quarter worth approximately $1,992,000. Finally, Stephens Investment Management Group LLC lifted its position in shares of Exelixis by 1.1% during the 4th quarter. Stephens Investment Management Group LLC now owns 2,539,421 shares of the biotechnology company’s stock worth $111,303,000 after buying an additional 28,265 shares during the period. 85.27% of the stock is currently owned by institutional investors.

Exelixis Price Performance

EXEL stock opened at $53.96 on Thursday. The business has a fifty day moving average price of $50.18 and a 200 day moving average price of $45.80. Exelixis, Inc. has a fifty-two week low of $33.76 and a fifty-two week high of $55.91. The stock has a market capitalization of $13.56 billion, a price-to-earnings ratio of 17.93, a P/E/G ratio of 1.57 and a beta of 0.42.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.12. The company had revenue of $610.81 million for the quarter, compared to analyst estimates of $607.51 million. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The business’s revenue was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.55 earnings per share. On average, equities analysts expect that Exelixis, Inc. will post 3.16 earnings per share for the current fiscal year.

Insider Activity

In other Exelixis news, Director Sue Gail Eckhardt sold 9,812 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $50.14, for a total value of $491,973.68. Following the completion of the transaction, the director directly owned 16,079 shares of the company’s stock, valued at approximately $806,201.06. The trade was a 37.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrick J. Haley sold 32,110 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $49.81, for a total transaction of $1,599,399.10. Following the transaction, the executive vice president owned 357,638 shares in the company, valued at $17,813,948.78. The trade was a 8.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 219,170 shares of company stock worth $10,620,641. 2.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

EXEL has been the topic of a number of analyst reports. Wall Street Zen upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Barclays lifted their price objective on Exelixis from $44.00 to $45.00 and gave the company an “equal weight” rating in a report on Monday, April 20th. Stifel Nicolaus boosted their target price on shares of Exelixis from $44.00 to $47.00 and gave the company a “hold” rating in a research note on Wednesday, May 6th. Morgan Stanley reiterated a “positive” rating on shares of Exelixis in a research report on Monday, June 22nd. Finally, Zacks Research downgraded shares of Exelixis from a “strong-buy” rating to a “hold” rating in a report on Thursday, March 5th. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $46.87.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.